In Silico Modeling and Validation of Uricase Enzyme, an Anti-Gout Drug

Abstract

Background
The microbial Uricase enzyme can be employed as an effective drug to cure hyperuricemia related disorders in human beings in particular gout disease and refractory gout which is developed in humans due to effects of some anti-gout synthetic drugs. Various microbes have been reported to produce Uricase. The production of Uricase enzyme by microorganisms is an economical and environmental friendly process compared to manufacturing protocols of synthetic drugs used for the same. The therapeutic enzyme, Uircase can be modified and improved by using the tools of computational biology.
Materials and methods
From UniProt Knowledgebase server the sequence of a bacterial Uricase enzyme in FASTA format was downloaded and entered in SWISS-MODEL server to develop the respective model of Uricase enzyme. The Uricase model quality was determined by using Procheck and Verify 3D online servers.
Results
The Uricase enzyme sequence of bacterium, Arthrobacter globiformis was procured from UniProt server. The enzyme sequence was used to develop model structure of Uricase in SWISS-MODEL server by automated model. The model quality of Uricase enzyme was checked and validated in Procheck server using Ramachandran Plot and Verify 3D server based on model quality score.
Conclusion
The bioinformatics tools can be exploited to design, model and improve the commercially important biomolecules. The proteins are the important biomolecules which can be improved by computational tools. Further the therapeutic value of Uricase enzyme can be enhanced by employing computational tools.